On October 23, 2024 Circio Holding ASA’s (the "Company") reported outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023 (Press release, Circio, OCT 23, 2024, View Source [SID1234647333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 500,000 which, pursuant to the bond terms, are convertible into 833,333 new shares in the Company at a conversion price of NOK 0.6.

The Company’s share capital will accordingly be increased by NOK 499,999.80 by the issuance of 833,333 new shares upon completion of the conversion by registration of the share capital increase in the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company’s total share capital will be NOK 15,211,804.20 divided into 25,353,007 shares, each with a nominal value of NOK 0.60.